Physician profile
Ryan Wayne Seidl
NPI 1821599143
$2,457.95
in general payments reported to CMS, 2019-2025
31 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $810 · 2022: $958 · 2023: $425 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $354.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $257.43 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $217.20 | 2021-2025 | Fasenra, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $200.42 | 2021-2025 | |
| Abbvie INC. | $160.39 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $123.29 | 2021-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $121.26 | 2021-2023 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $113.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $101.56 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.01 | 2021-2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.02 | 2021-2023 | Jardiance |
| Arbor Pharmaceuticals, INC. | $68.47 | 2021 | |
| Optinose US, INC. | $64.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $51.76 | 2021-2022 | |
| Abbott Laboratories | $50.87 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $48.25 | 2021 | |
| Dexcom, INC. | $47.13 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $42.60 | 2021 | |
| Exact Sciences Corporation | $39.63 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $31.59 | 2021 | |
| Esperion Therapeutics, INC. | $23.16 | 2021 | |
| Genentech USA, INC. | $20.22 | 2021 | |
| Corcept Therapeutics | $19.50 | 2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $17.85 | 2025 | Azmiro |
| Corvista Health, INC. | $17.78 | 2025 | Corvista System |
| Otsuka America Pharmaceutical, INC. | $16.99 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $16.58 | 2022 | |
| Shield Therapeutics INC | $15.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $15.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.10 | 2022 | |
| Pfizer INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Seidl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.